Home > Dermatology > AAD 2022 > New Developments and Unmet Needs in Dermatology > Alopecia areata: 1-year baricitinib treatment increases success

Alopecia areata: 1-year baricitinib treatment increases success

Presented By
Prof. Brett King, Yale School of Medicine, USA
Presented by
Brett King
Conference
AAD 2022
Trial
Phase 3, BRAVE-AA1; BRAVE-AA2
Long-term results of the phase 3 BRAVE-AA1 and BRAVE-AA2 trials demonstrated that extended treatment of alopecia areata with baricitinib for up to 52 weeks increased the percentage of patients responding with regrowth of hair. Benefits were not only observed on the scalp but also in the eyebrows and eyelashes. As the Janus kinase (JAK)-dependent cytokines IL-15 and IFN-γ form part of the pathogenesis of alopecia areata, JAK inhibition is a recent focus of treatment research [1–3]. “Every meeting we are getting closer and closer to approved therapies for our patients, who are suffering from this disease,” Prof. Brett King (Yale School of Medicine, CT, USA) said [4]. Prof. King presented the 52-week data from the extension periods of the phase 3 BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on